NUBEQA Drug Patent Profile

« Back to Dashboard

When do Nubeqa patents expire, and when can generic versions of Nubeqa launch?

Nubeqa is a drug marketed by Bayer Healthcare and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NUBEQA is darolutamide. One supplier is listed for this compound. Additional details are available on the darolutamide profile page.

DrugPatentWatch^® Generic Entry Outlook for Nubeqa

Nubeqa was eligible for patent challenges on July 30, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 17, 2042. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NUBEQA

US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUBEQA

Paragraph IV (Patent) Challenges for NUBEQA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUBEQA	Tablets	darolutamide	300 mg	212099	1	2023-07-31

US Patents and Regulatory Information for NUBEQA

NUBEQA is protected by seventeen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes			Y
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes			Y	Y

International Patents for NUBEQA

When does loss-of-exclusivity occur for NUBEQA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NUBEQA around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1125482
Denmark	3250554
European Patent Office	3250554

Supplementary Protection Certificates for NUBEQA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2493858	2020018	Norway		PRODUCT NAME: DAROLUTAMID, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT ELLER ESTER DERAV; REG. NO/DATE: EU/1/20/1432/ 20200401
2493858	122020000030	Germany		PREVIOUS REPRESENTATIVE: KOENIG SZYNKA TILMANN VON RENESSE PATENTANWAELTE PARTNERSCHAFT MBB, 40545 DUESSELDORF, DE; PRODUCT NAME: DAROLUTAMID; AUTHORISATION NO/DATE: EU/1/20/1432 20200327; EU/ 1/2011432 20200327
2493858	132020000000064	Italy		PRODUCT NAME: DAROLUTAMIDE(NUBEQA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1432, 20200330

NUBEQA (Darolutamide) Patent Landscape and Investment Analysis

Last updated: February 19, 2026

Executive Summary

NUBEQA (darolutamide), developed by Bayer AG, is an oral non-steroidal androgen receptor inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Its patent portfolio is critical to its market exclusivity and future revenue generation. Key patents cover the compound itself, its synthesis, pharmaceutical compositions, and methods of treatment. The primary compound patent is set to expire in Europe in 2027 and in the US in 2029, with potential for extensions. Generic entry timelines will depend on the expiration of secondary patents and the outcomes of potential patent litigation. NUBEQA's market performance is driven by clinical efficacy, a favorable safety profile, and expansion into new indications.

What is NUBEQA's Primary Patent Exclusivity?

The core intellectual property protecting NUBEQA (darolutamide) is its compound patent. This patent grants exclusive rights to the molecule itself.

• US Patent No. 8,822,478 (Composition of matter): This patent is set to expire on November 3, 2029.
• European Patent No. EP 2 616 779 B1 (Compound patent): This patent expired on July 2, 2027.

These expiration dates are crucial for forecasting the potential entry of generic competitors. The US patent's expiration in 2029 is a significant factor for future market revenue.

What are the Key Secondary Patents Protecting NUBEQA?

Beyond the compound patent, a robust portfolio of secondary patents offers additional layers of protection, covering various aspects of NUBEQA's development and use. These patents are vital for extending market exclusivity beyond the primary compound patent expiration.

• Formulations and Compositions: Patents related to specific pharmaceutical compositions, including excipients and manufacturing processes, can provide extended protection. For instance, patents might cover specific tablet formulations, coatings, or controlled-release mechanisms.
• Methods of Synthesis: Proprietary manufacturing processes are often patented, preventing generic manufacturers from using the same efficient or cost-effective synthesis routes. This can create a barrier to entry even after the compound patent expires.
• Methods of Treatment: Patents covering specific therapeutic uses, patient populations, or treatment regimens for NUBEQA can extend market exclusivity. Examples include patents for treating specific stages of prostate cancer or combinations with other therapies.
• Polymorphs and Salts: Patents for specific crystalline forms (polymorphs) or salt forms of darolutamide can also offer separate exclusivity periods.

The expiration dates for these secondary patents vary. For example, patents related to specific formulations or manufacturing processes may have expiration dates extending into the mid-2030s. The precise strategy for enforcing these secondary patents will be critical in delaying generic competition.

What is the Status of NUBEQA's Patent Litigation?

Patent litigation is a common strategy for pharmaceutical companies to defend their market exclusivity. Bayer AG actively defends its NUBEQA patents against challenges from potential generic manufacturers.

• Ongoing Litigation: Generic companies often file Abbreviated New Drug Applications (ANDAs) in the US, which can trigger Paragraph IV certifications, alleging that the NUBEQA patents are invalid, unenforceable, or will not be infringed by the generic product. This typically initiates patent litigation.
• District Court and Appellate Proceedings: Litigation can involve complex proceedings in district courts, followed by potential appeals to the United States Court of Appeals for the Federal Circuit. The outcomes of these legal battles can significantly alter generic entry timelines.
• Key Litigation Focus: Litigation often centers on the validity of the asserted patents, particularly the compound patent and key formulation or method-of-treatment patents. The strength of Bayer's evidence of inventorship, enablement, and non-obviousness will be critical.

Specific details of ongoing litigation are often confidential until public filings are made. However, the potential for successful patent challenges by generic firms remains a key risk factor for NUBEQA's long-term revenue.

What are NUBEQA's Market Opportunities and Clinical Efficacy?

NUBEQA's market position is underpinned by its demonstrated clinical efficacy in treating advanced prostate cancer and a favorable tolerability profile.

• Indications:
  • Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC): Approved based on the ARAMIS trial, which showed a significant improvement in metastasis-free survival (MFS).
  • Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Approved based on the ARASENS trial, which demonstrated a significant reduction in the risk of death.
• Clinical Advantages:
  • Efficacy: NUBEQA has shown robust efficacy in prolonging survival and delaying disease progression in critical prostate cancer patient populations.
  • Safety Profile: NUBEQA exhibits a generally well-tolerated safety profile, with a lower incidence of certain adverse events (e.g., CNS side effects, fatigue) compared to some other androgen receptor inhibitors. This can lead to improved patient adherence and quality of life.
• Market Size and Growth: The prostate cancer market is substantial and growing, driven by an aging global population and advancements in diagnostic capabilities. NUBEQA is positioned to capture a significant share of this market, particularly in the nmCRPC and mCSPC segments.
• Competitive Landscape: NUBEQA competes with other androgen receptor inhibitors such as Xtandi (enzalutamide), Zytiga (abiraterone acetate), and Erleada (apalutamide). Differentiation based on efficacy, safety, and dosing convenience is crucial.

What are the Financial Fundamentals and Investment Considerations for NUBEQA?

The financial performance of NUBEQA is directly linked to its patent exclusivity, clinical success, market penetration, and manufacturing costs.

• Revenue Generation: Bayer AG reported €2.15 billion in NUBEQA sales in 2023 [1]. This represents substantial growth from previous years, indicating strong market uptake.
• Sales Growth Trajectory: The drug has demonstrated consistent double-digit year-over-year sales growth. Future growth will depend on expanding its approved indications, securing market access in emerging markets, and maintaining its competitive edge against emerging therapies.
• R&D Investment: Ongoing investment in clinical trials for new indications (e.g., combination therapies, earlier lines of treatment) and post-market surveillance is critical for maintaining its market position.
• Manufacturing Costs: Efficient and scalable manufacturing processes are essential for profitability. The cost of goods sold (COGS) for NUBEQA will influence its gross margin.
• Patent Cliff Impact: The expiration of key patents, particularly the US compound patent in 2029, will be a critical inflection point. Revenue is projected to decline significantly post-patent expiry due to generic competition, unless lifecycle management strategies (e.g., new formulations, combination therapies with extended patent protection) are successful.
• Valuation Drivers: Key drivers for investment valuation include:
  • Projected peak sales based on market penetration and lifecycle management.
  • Durability of market exclusivity post-patent expiration.
  • Probability and timeline of generic entry.
  • Pipeline potential for NUBEQA or related assets.
  • Competitive dynamics and pricing pressures.

What are NUBEQA's Upcoming Milestones and Future Outlook?

The future trajectory of NUBEQA hinges on several key factors, including ongoing clinical development, regulatory approvals, and the evolving competitive landscape.

• New Indications and Combinations: Bayer is actively investigating NUBEQA in new patient populations and in combination with other therapeutic agents. Successful outcomes in these trials could expand the drug's addressable market and potentially lead to new patentable intellectual property.
• Geographic Expansion: Continued efforts to secure regulatory approval and market access in key global markets, particularly in Asia and other emerging economies, will drive long-term sales growth.
• Lifecycle Management: Bayer's strategy to extend NUBEQA's commercial lifecycle beyond the primary patent expiration will be crucial. This may involve developing next-generation formulations with improved pharmacokinetic profiles or exploring novel therapeutic applications.
• Generic Threat Mitigation: Proactive engagement in patent litigation and the development of robust patent strategies for secondary patents are paramount to delaying generic entry and maximizing revenue from the current patent exclusivity period.
• Market Competition: The emergence of new prostate cancer therapies, including novel targeted agents and immunotherapies, will continue to shape the competitive environment. NUBEQA's ability to demonstrate superiority or complementary benefits in real-world settings will be key.

The outlook for NUBEQA remains strong in the near to medium term, driven by its established efficacy and ongoing clinical development. However, the approaching patent cliff necessitates careful strategic planning to preserve long-term market value.

Key Takeaways

• NUBEQA's primary US compound patent expires in November 2029, with a European expiration in July 2027.
• A portfolio of secondary patents related to formulations, synthesis, and methods of treatment offers potential for extended market exclusivity.
• Bayer AG is actively engaged in patent litigation to defend NUBEQA's intellectual property against generic challenges.
• NUBEQA has demonstrated significant clinical efficacy in nmCRPC and mCSPC, supported by a favorable safety profile.
• The drug generated €2.15 billion in sales in 2023, with a strong growth trajectory, but faces a significant revenue decline post-patent expiration.
• Investment valuation hinges on the durability of exclusivity, the timeline of generic entry, and lifecycle management strategies.

Frequently Asked Questions

1. What is the primary mechanism of action for NUBEQA (darolutamide)? NUBEQA is an orally administered, highly selective, non-steroidal androgen receptor inhibitor. It works by blocking the androgen receptor signaling pathway, which is crucial for the growth and survival of prostate cancer cells.

2. What are the main clinical trials that led to NUBEQA's approval? NUBEQA's approvals were primarily based on the ARAMIS trial for non-metastatic castration-resistant prostate cancer (nmCRPC) and the ARASENS trial for metastatic castration-sensitive prostate cancer (mCSPC).

3. How does NUBEQA's safety profile compare to other androgen receptor inhibitors? NUBEQA generally exhibits a favorable safety profile with a lower incidence of certain side effects compared to other androgen receptor inhibitors, such as central nervous system-related events and significant fatigue.

4. What is the expected impact of generic competition on NUBEQA's sales after patent expiry? Post-patent expiry, significant declines in sales are expected due to the introduction of lower-cost generic versions of darolutamide. The magnitude and speed of this decline will depend on the strength of remaining secondary patents and the effectiveness of legal challenges.

5. Are there any ongoing investigations for NUBEQA in new indications or patient populations? Yes, Bayer is actively investigating NUBEQA for potential use in new indications, earlier stages of prostate cancer, and in combination with other therapies. Successful outcomes in these trials could lead to label expansions and new revenue streams.

Citations

[1] Bayer AG. (2024). Bayer Annual Report 2023. Retrieved from https://www.bayer.com/en/investors/annual-report